Therapeutic Area
Heart Failure Clinical Trials — Amavita Research
Cardiovascular trial site for heart failure, conducted at amavita Heart and Vascular Health® in North Miami Beach, FL.
Heart failure affects roughly 6.7 million U.S. adults and accounts for more than one million hospitalizations each year. The pipeline now spans HFpEF and HFrEF with novel mechanisms — neuregulin-1 fusion proteins, structural-remodeling agents, anti-inflammatory therapies, and device-based approaches. Here is what Amavita Research is currently running in this space.
Active trials at Amavita Research
- RENEU-HF — JK07 for Chronic Heart Failure
Sponsor: Salubris Biotherapeutics (JK07 Bio) · Phase 2
Phase 2 RENEU-HF study of JK07, an investigational neuregulin-1 fusion protein for chronic heart failure.
- VS-041 — HFpEF (Pfizer)
Sponsor: Pfizer · Phase 2
Investigational therapy targeting cardiac structural remodeling in heart failure with preserved ejection fraction (HFpEF).
Principal Investigators in this area
Why Amavita Research for heart failure trials
- Triple-board-certified electrophysiologist on staff (Dr. Hans C. Rutzen-Lopez, MD) — ICD/CRT-D device experience and ECG-gated trial assessments.
- Cath-lab access via amavita Heart and Vascular Health® and the affiliated Advanced Cardiovascular of Miami ambulatory surgical center.
- Both HFpEF and HFrEF patient cohorts already engaged through routine cardiology care at the parent practice.
- On-site IV infusion suite for trial dosing protocols (e.g., IV inotropes, IV diuretics).
- Same-day NT-proBNP, troponin, and hs-CRP central-lab handling per ICH-GCP E6(R3).
Think you might be eligible for a heart failure trial?
Call (786) 703-5941 or use the patient contact form — initial screening is free and takes about 15 minutes.